16:24 EST Aardvark Thera sees cash, equivalents sufficient to fund operations into 2027
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics, Inc.: Undervalued Potential in the Obesity Treatment Market with Promising Pipeline
- Datadog, Trade Desk upgraded: Wall Street’s top analyst calls
- Aardvark Therapeutics initiated with a Buy at BTIG
- Aardvark Therapeutics Hosts Investor Webinar on Drug Programs
- Promising Potential of Aardvark Therapeutics: Buy Rating Based on ARD-201 and ARD-101 Developments